With approximately 10 approved products and several under development, the Herceptin® biosimilars market is projected to witness considerable growth over the coming years, claims Roots Analysis
Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated opportunity, stakeholders in the pharma industry have long been developing follow on products
For additional details, please visit
https://www.rootsanalysis.com/....reports/biopharmaceu
Like
Comment
Share
